Search

Your search keyword '"Camerini, Andrea"' showing total 227 results
Start Over Author "Camerini, Andrea"
227 results on '"Camerini, Andrea"'

1. Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed

Author

Leonetti, Alessandro, Perrone, Fabiana, Puntoni, Matteo, Maglietta, Giuseppe, Bordi, Paola, Bria, Emilio, Vita, Emanuele, Gelsomino, Francesco, De Giglio, Andrea, Gelibter, Alain, Siringo, Marco, Mazzoni, Francesca, Caliman, Enrico, Genova, Carlo, Bertolini, Federica, Guaitoli, Giorgia, Passiglia, Francesco, Delcuratolo, Marco Donatello, Montrone, Michele, Cerea, Giulio, Pasello, Giulia, Roca, Elisa, Belluomini, Lorenzo, Cecere, Fabiana Letizia, Guida, Annalisa, Manzo, Anna, Adamo, Vincenzo, Rastelli, Francesca, Bulotta, Alessandra, Citarella, Fabrizio, Toschi, Luca, Zoratto, Federica, Cortinovis, Diego Luigi, Berardi, Rossana, Follador, Alessandro, Carta, Annamaria, Camerini, Andrea, Salerno, Flavio, Silva, Rosa Rita, Baldini, Editta, Cortellini, Alessio, Brighenti, Matteo, Santoni, Matteo, Malorgio, Francesco, Caminiti, Caterina, and Tiseo, Marcello

Published
2024
Full Text
View/download PDF

2. Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysis

Author

Anpalakhan, Shobana, Signori, Alessio, Cortellini, Alessio, Verzoni, Elena, Giusti, Raffaele, Aprile, Giuseppe, Ermacora, Paola, Catino, Annamaria, Pipitone, Stefania, Di Napoli, Marilena, Scotti, Vieri, Mazzoni, Francesca, Guglielmini, Pamela F., Veccia, Antonello, Maruzzo, Marco, Schinzari, Giovanni, Casadei, Chiara, Grossi, Francesco, Rizzo, Mimma, Montesarchio, Vincenzo, Verderame, Francesco, Mencoboni, Manlio, Zustovich, Fable, Fratino, Lucia, Accettura, Caterina, Cinieri, Saverio, Tondini, Carlo Alberto, Camerini, Andrea, Banzi, Maria Chiara, Sorarù, Mariella, Zucali, Paolo Andrea, Vignani, Francesca, Ricciardi, Serena, Russo, Antonio, Cosenza, Agnese, Di Maio, Massimo, De Giorgi, Ugo, Pignata, Sandro, Giannarelli, Diana, Pinto, Carmine, Buti, Sebastiano, Fornarini, Giuseppe, Rebuzzi, Sara Elena, Rescigno, Pasquale, Addeo, Alfredo, Banna, Giuseppe L., and Bersanelli, Melissa

Published
2023
Full Text
View/download PDF

3. Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2): final results of the multicentre, prospective, observational study

Author

Bersanelli, Melissa, Verzoni, Elena, Cortellini, Alessio, Giusti, Raffaele, Calvetti, Lorenzo, Ermacora, Paola, Di Napoli, Marilena, Catino, Annamaria, Guadalupi, Valentina, Guaitoli, Giorgia, Scotti, Vieri, Mazzoni, Francesca, Veccia, Antonello, Guglielmini, Pamela Francesca, Perrone, Fabiana, Maruzzo, Marco, Rossi, Ernesto, Casadei, Chiara, Montesarchio, Vincenzo, Grossi, Francesco, Rizzo, Mimma, Travagliato Liboria, Maria Grazia, Mencoboni, Manlio, Zustovich, Fable, Fratino, Lucia, Accettura, Caterina, Cinieri, Saverio, Camerini, Andrea, Sorarù, Mariella, Zucali, Paolo Andrea, Ricciardi, Serena, Russo, Antonio, Negrini, Giorgia, Banzi, Maria Chiara, Lacidogna, Gaetano, Fornarini, Giuseppe, Laera, Letizia, Mucciarini, Claudia, Santoni, Matteo, Mosillo, Claudia, Bonetti, Andrea, Longo, Lucia, Sartori, Donata, Baldini, Editta, Guida, Michele, Iannopollo, Mauro, Bordonaro, Roberto, Morelli, Maria Francesca, Tagliaferri, Pierosandro, Spada, Massimiliano, Ceribelli, Anna, Silva, Rosa Rita, Nolè, Franco, Beretta, Giordano, Giovanis, Petros, Santini, Daniele, Luzi Fedeli, Stefano, Nanni, Oriana, Maiello, Evaristo, Labianca, Roberto, Pinto, Carmine, Clemente, Alberto, Tognetto, Michele, De Giorgi, Ugo, Pignata, Sandro, Di Maio, Massimo, Buti, Sebastiano, and Giannarelli, Diana

Published
2023
Full Text
View/download PDF

5. Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy

Author

Mountzios, Giannis, de Toma, Alessandro, Economopoulou, Panagiota, Friedlaender, Alex, Banini, Marco, Lo Russo, Giuseppe, Baxevanos, Panagiotis, Roila, Fausto, Banna, Giuseppe Luigi, Christopoulou, Athina, Jimenez, Beatriz, Collazo-Lorduy, Ana, Linardou, Helena, Calles, Antonio, Galetta, Domenico, Addeo, Alfredo, Camerini, Andrea, Pizzutilo, Pamela, Kosmidis, Paris, Garassino, Marina Chiara, Proto, Claudia, Signorelli, Diego, and Metro, Giulio

Published
2021
Full Text
View/download PDF

6. Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed

Author

Leonetti, A, Perrone, F, Puntoni, M, Maglietta, G, Bordi, P, Bria, E, Vita, E, Gelsomino, F, De Giglio, A, Gelibter, A, Siringo, M, Mazzoni, F, Caliman, E, Genova, C, Bertolini, F, Guaitoli, G, Passiglia, F, Delcuratolo, M, Montrone, M, Cerea, G, Pasello, G, Roca, E, Belluomini, L, Cecere, F, Guida, A, Manzo, A, Adamo, V, Rastelli, F, Bulotta, A, Citarella, F, Toschi, L, Zoratto, F, Cortinovis, D, Berardi, R, Follador, A, Carta, A, Camerini, A, Salerno, F, Silva, R, Baldini, E, Cortellini, A, Brighenti, M, Santoni, M, Malorgio, F, Caminiti, C, Tiseo, M, Leonetti, Alessandro, Perrone, Fabiana, Puntoni, Matteo, Maglietta, Giuseppe, Bordi, Paola, Bria, Emilio, Vita, Emanuele, Gelsomino, Francesco, De Giglio, Andrea, Gelibter, Alain, Siringo, Marco, Mazzoni, Francesca, Caliman, Enrico, Genova, Carlo, Bertolini, Federica, Guaitoli, Giorgia, Passiglia, Francesco, Delcuratolo, Marco Donatello, Montrone, Michele, Cerea, Giulio, Pasello, Giulia, Roca, Elisa, Belluomini, Lorenzo, Cecere, Fabiana Letizia, Guida, Annalisa, Manzo, Anna, Adamo, Vincenzo, Rastelli, Francesca, Bulotta, Alessandra, Citarella, Fabrizio, Toschi, Luca, Zoratto, Federica, Cortinovis, Diego Luigi, Berardi, Rossana, Follador, Alessandro, Carta, Annamaria, Camerini, Andrea, Salerno, Flavio, Silva, Rosa Rita, Baldini, Editta, Cortellini, Alessio, Brighenti, Matteo, Santoni, Matteo, Malorgio, Francesco, Caminiti, Caterina, Tiseo, Marcello, Leonetti, A, Perrone, F, Puntoni, M, Maglietta, G, Bordi, P, Bria, E, Vita, E, Gelsomino, F, De Giglio, A, Gelibter, A, Siringo, M, Mazzoni, F, Caliman, E, Genova, C, Bertolini, F, Guaitoli, G, Passiglia, F, Delcuratolo, M, Montrone, M, Cerea, G, Pasello, G, Roca, E, Belluomini, L, Cecere, F, Guida, A, Manzo, A, Adamo, V, Rastelli, F, Bulotta, A, Citarella, F, Toschi, L, Zoratto, F, Cortinovis, D, Berardi, R, Follador, A, Carta, A, Camerini, A, Salerno, F, Silva, R, Baldini, E, Cortellini, A, Brighenti, M, Santoni, M, Malorgio, F, Caminiti, C, Tiseo, M, Leonetti, Alessandro, Perrone, Fabiana, Puntoni, Matteo, Maglietta, Giuseppe, Bordi, Paola, Bria, Emilio, Vita, Emanuele, Gelsomino, Francesco, De Giglio, Andrea, Gelibter, Alain, Siringo, Marco, Mazzoni, Francesca, Caliman, Enrico, Genova, Carlo, Bertolini, Federica, Guaitoli, Giorgia, Passiglia, Francesco, Delcuratolo, Marco Donatello, Montrone, Michele, Cerea, Giulio, Pasello, Giulia, Roca, Elisa, Belluomini, Lorenzo, Cecere, Fabiana Letizia, Guida, Annalisa, Manzo, Anna, Adamo, Vincenzo, Rastelli, Francesca, Bulotta, Alessandra, Citarella, Fabrizio, Toschi, Luca, Zoratto, Federica, Cortinovis, Diego Luigi, Berardi, Rossana, Follador, Alessandro, Carta, Annamaria, Camerini, Andrea, Salerno, Flavio, Silva, Rosa Rita, Baldini, Editta, Cortellini, Alessio, Brighenti, Matteo, Santoni, Matteo, Malorgio, Francesco, Caminiti, Caterina, and Tiseo, Marcello

Abstract

Purpose: The aim of this multi-center, retrospective/prospective cohort observational study was to evaluate outcomes in routine clinical practice of first-line chemo-immunotherapy with cis/carboplatin, pemetrexed and pembrolizumab in patients with advanced non-squamous non-small cell lung cancer (NSCLC) in 33 Italian centers. Methods: The outcome measure was to evaluate overall survival (OS) in a real-world patient population. Secondary endpoints were: progression-free survival (PFS), objective response rate (ORR), duration of response (DoR) and incidence of treatment-related adverse events (AEs). Results: 1068 patients were enrolled at the time of data cut-off (January 31st, 2023), and 812 (76.0%) belonged to the retrospective cohort. Median age was 66 years (27−85), ECOG PS was ≥ 2 in 91 (8.6%) patients; 254 (23.8%) patients had brain metastases at baseline; 38 (3.6%) patients had tumor with PD-L1 expression ≥ 50%. After a median follow-up of 17.0 months (95% CI, 16.1–17.9), median OS was 16.1 months (95% CI, 14.4–18.8) and PFS was 9.9 months (95% CI, 8.8–11.2). Median DoR (n = 493) was 14.7 months (95% CI, 13.6–17.1). ORR was 43.4% (95% CI, 40.4–46.4). Any-grade AEs occurred in 636 (59.6%) patients and grade ≥ 3 in 253 (23.7%) patients. Most common grade ≥ 3 AEs were neutropenia (6.3%) and anemia (6.3%). Conclusions: First-line chemo-immunotherapy was effective and tolerable in this large, real-world Italian study of patients with advanced non-squamous NSCLC. Our results were in line with the KEYNOTE-189 registration study, also considering the low number of PD-L1 ≥ 50% patients included in our study.

Published
2024

8. Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations

Author

Passaro, Antonio, Prelaj, Arsela, Bonanno, Laura, Tiseo, Marcello, Tuzi, Alessandro, Proto, Claudia, Chiari, Rita, Rocco, Danilo, Genova, Carlo, Sini, Claudio, Cortinovis, Diego, Pilotto, Sara, Landi, Lorenza, Bennati, Chiara, Camerini, Andrea, Toschi, Luca, Putzu, Carlo, Cerea, Giulio, Spitaleri, Gianluca, Cappuzzo, Federico, and de Marinis, Filippo

Published
2019
Full Text
View/download PDF

9. Corrigendum: Cancer survivorship at heart: a multidisciplinary cardio-oncology roadmap for healthcare professionals

Author

Bisceglia, Irma, primary, Canale, Maria Laura, additional, Silvestris, Nicola, additional, Gallucci, Giuseppina, additional, Camerini, Andrea, additional, Inno, Alessandro, additional, Camilli, Massimiliano, additional, Turazza, Fabio Maria, additional, Russo, Giulia, additional, Paccone, Andrea, additional, Mistrulli, Raffaella, additional, De Luca, Leonardo, additional, Di Fusco, Stefania Angela, additional, Tarantini, Luigi, additional, Lucà, Fabiana, additional, Oliva, Stefano, additional, Moreo, Antonella, additional, Maurea, Nicola, additional, Quagliariello, Vincenzo, additional, Ricciardi, Giuseppina Rosaria, additional, Lestuzzi, Chiara, additional, Fiscella, Damiana, additional, Parrini, Iris, additional, Racanelli, Vito, additional, Russo, Antonio, additional, Incorvaia, Lorena, additional, Calabrò, Fabio, additional, Curigliano, Giuseppe, additional, Cinieri, Saverio, additional, Gulizia, Michele Massimo, additional, Gabrielli, Domenico, additional, Oliva, Fabrizio, additional, and Colivicchi, Furio, additional

Published
2023
Full Text
View/download PDF

10. Cancer survivorship at heart: a multidisciplinary cardio-oncology roadmap for healthcare professionals

Author

Bisceglia, Irma, primary, Canale, Maria Laura, additional, Silvestris, Nicola, additional, Gallucci, Giuseppina, additional, Camerini, Andrea, additional, Inno, Alessandro, additional, Camilli, Massimiliano, additional, Turazza, Fabio Maria, additional, Russo, Giulia, additional, Paccone, Andrea, additional, Mistrulli, Raffaella, additional, De Luca, Leonardo, additional, Di Fusco, Stefania Angela, additional, Tarantini, Luigi, additional, Lucà, Fabiana, additional, Oliva, Stefano, additional, Moreo, Antonella, additional, Maurea, Nicola, additional, Quagliariello, Vincenzo, additional, Ricciardi, Giuseppina Rosaria, additional, Lestuzzi, Chiara, additional, Fiscella, Damiana, additional, Parrini, Iris, additional, Racanelli, Vito, additional, Russo, Antonio, additional, Incorvaia, Lorena, additional, Calabrò, Fabio, additional, Curigliano, Giuseppe, additional, Cinieri, Saverio, additional, Gulizia, Michele Massimo, additional, Gabrielli, Domenico, additional, Oliva, Fabrizio, additional, and Colivicchi, Furio, additional

Published
2023
Full Text
View/download PDF

11. Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain Metastases From Advanced Non–Small Cell Lung Cancer With a PD-L1 Expression ≥50%

Author

Metro, Giulio, Banna, Giuseppe Luigi, Signorelli, Diego, Gili, Alessio, Galetta, Domenico, Galli, Giulia, Economopoulou, Panagiota, Roila, Fausto, Friedlaender, Alex, Camerini, Andrea, Christopoulou, Athina, Cantale, Ornella, De Toma, Alessandro, Pizzutilo, Pamela, Jimenez, Beatriz, Collazo-Lorduy, Ana, Calles, Antonio, Baxevanos, Panagiotis, Linardou, Helena, Kosmidis, Paris, Giannarelli, Diana, Mountzios, Giannis, and Addeo, Alfredo

Published
2020
Full Text
View/download PDF

12. Cardio-oncology rehabilitation: are we ready?

Author

Bisceglia, Irma, Venturini, Elio, Canale, Maria Laura, Ambrosetti, Marco, Riccio, Carmine, Giallauria, Francesco, Gallucci, Giuseppina, Abrignani, Maurizio G, Russo, Giulia, Lestuzzi, Chiara, Mistrulli, Raffaella, De Luca, Giovanni, Maria Turazza, Fabio, Mureddu, Gianfrancesco, Di Fusco, Stefania Angela, Lucà, Fabiana, De Luca, Leonardo, Camerini, Andrea, Halasz, Geza, Camilli, Massimiliano, Quagliariello, Vincenzo, Maurea, Nicola, Fattirolli, Francesco, Gulizia, Michele Massimo, Gabrielli, Domenico, Grimaldi, Massimo, Colivicchi, Furio, and Oliva, Fabrizio

Abstract

Cardio-oncology rehabilitation (CORE) is not only an essential component of cancer rehabilitation but also a pillar of preventive cardio-oncology. Cardio-oncology rehabilitation is a comprehensive model based on a multitargeted approach and its efficacy has been widely documented; when compared with an ‘exercise only’ programme, comprehensive CORE demonstrates a better outcome. It involves nutritional counselling, psychological support, and cardiovascular (CV) risk assessment, and it is directed to a very demanding population with a heavy burden of CV diseases driven by physical inactivity, cancer therapy-induced metabolic derangements, and cancer therapy-related CV toxicities. Despite its usefulness, CORE is still underused in cancer patients and we are still at the dawning of remote models of rehabilitation (tele-rehabilitation). Not all CORE is created equally: a careful screening procedure to identify patients who will benefit the most from CORE and a multidisciplinary customized approach are mandatory to achieve a better outcome for cancer survivors throughout their cancer journey. The aim of this paper is to provide an updated review of CORE not only for cardiologists dealing with this peculiar population of patients but also for oncologists, primary care providers, patients, and caregivers. This multidisciplinary team should help cancer patients to maintain a healthy and active life before, during, and after cancer treatment, in order to improve quality of life and to fight health inequities.

Published
2024
Full Text
View/download PDF

14. Baseline Troponin Level and Cardiac Toxicity in HER2-positive Early Breast Cancer Patients Receiving Trastuzumab.

Author

CANALE, MARIA LAURA, CASOLO, GIANCARLO, DONATI, SARA, BISCEGLIA, IRMA, PUCCETTI, CHETI, AMOROSO, DOMENICO, VENTURINI, ELIO, MAUREA, NICOLA, TURAZZA, FABIO MARIA, and CAMERINI, ANDREA

Subjects
CARDIOTOXICITY, HER2 protein, BREAST cancer, TROPONIN, TRASTUZUMAB, VENTRICULAR ejection fraction
Abstract

Background/Aim: There is controversy around the use of high-sensitive troponin T (hs-TnT) as an early biomarker of cardiac toxicity in patients with breast cancer on trastuzumab (T). Patients and Methods: Patients receiving adjuvant or neo-adjuvant T for early HER2- positive breast cancer were prospectively included. Transthoracic echocardiograms and matched hs-TnT before T and at 3, 6, and 9 months were performed on all patients. Congestive heart failure, cardiac death, a decline in left ventricular ejection fraction (LVEF) of more than 10% from baseline even if it is still within the normal range, or a drop in LVEF below 55% were all considered signs of cardiac toxicity. Results: In total, 24 patients (median age: 57; range=39-79 years) were enrolled. Anthracyclines were administered to all patients but three as part of neo/adjuvant treatment before T. Cardiovascular toxicity was observed in 3 out of 24 (12.5%) patients: two nonsymptomatic LVEF declines (8.3%) and one heart failure episode (4.2%). In the entire population, the mean baseline hs-TnT level was 10.1±8.8 pg/ml, and after 3, 6, and 12 months, no appreciable change was observed. Patients with cardiac toxicity had mean hs-TnT levels higher than those without (18.3±12.3 vs. 8.2±7.2 pg/ml; p=0.049). A definite trend was evident in the chi-square test (chi 2=3.52; p=0.06). Conclusion: In anthracycline-exposed patients with early breast cancer, hs-TnT may be able to identify those at risk of developing cardiac toxicity during neo/adjuvant T treatment. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

15. Selection Criteria and Treatment Outcome for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Unfit for Platinum-Based First-Line Therapy: Results of the MOON-OSS Observational Trial

Author

Camerini, Andrea, primary, Del Conte, Alessandro, additional, Pezzuto, Aldo, additional, Scotti, Vieri, additional, Facchinetti, Francesco, additional, Ciccone, Lucia Pia, additional, Perna, Marco, additional, Sartori, Giulia, additional, Puccetti, Cheti, additional, Ricci, Alberto, additional, Santo, Antonio, additional, Tiseo, Marcello, additional, and Amoroso, Domenico, additional

Published
2022
Full Text
View/download PDF

16. Women at heart: Introducing gender cardio-oncology

Author

Canale, Maria Laura, primary, Bisceglia, Irma, additional, Gallucci, Giuseppina, additional, Russo, Giulia, additional, Camerini, Andrea, additional, Di Fusco, Stefania Angela, additional, Paccone, Andrea, additional, Camilli, Massimiliano, additional, Fiscella, Damiana, additional, Lestuzzi, Chiara, additional, Turazza, Fabio Maria, additional, Gulizia, Michele Massimo, additional, Pavan, Daniela, additional, Maurea, Nicola, additional, Gabrielli, Domenico, additional, Oliva, Fabrizio, additional, and Colivicchi, Furio, additional

Published
2022
Full Text
View/download PDF

17. Standard vs Adapted Sunitinib Regimen in Elderly Patients With Metastatic Renal Cell Cancer: Results From a Large Retrospective Analysis

Author

De Giorgi, Ugo, Scarpi, Emanuela, Sacco, Cosimo, Aieta, Michele, Lo Re, Giovanni, Sava, Teodoro, Masini, Cristina, De Vincenzo, Fabio, Baldazzi, Valentina, Camerini, Andrea, Fornarini, Giuseppe, Burattini, Luciano, Rosti, Giovanni, Ferrari, Vittorio, Moscetti, Luca, Chiuri, Vincenzo Emanuele, Luzi Fedeli, Stefano, Amadori, Dino, and Basso, Umberto

Published
2014
Full Text
View/download PDF

18. Lymphopenia and clinical outcome of elderly patients treated with sunitinib for metastatic renal cell cancer

Author

De Giorgi, Ugo, Rihawi, Karim, Aieta, Michele, Lo Re, Giovanni, Sava, Teodoro, Masini, Cristina, Baldazzi, Valentina, De Vincenzo, Fabio, Camerini, Andrea, Fornarini, Giuseppe, Burattini, Luciano, Rosti, Giovanni, Moscetti, Luca, Chiuri, Vincenzo E., Luzi Fedeli, Stefano, Ferrari, Vittorio, Scarpi, Emanuela, Amadori, Dino, and Basso, Umberto

Published
2014
Full Text
View/download PDF

19. Corrigendum: Portrait of Italian Cardio-Oncology: Results of a Nationwide Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO) Survey

Author

Canale, Maria Laura, primary, Turazza, Fabio, additional, Lestuzzi, Chiara, additional, Parrini, Iris, additional, Camerini, Andrea, additional, Russo, Giulia, additional, Colivicchi, Furio, additional, Gabrielli, Domenico, additional, Gulizia, Michele Massimo, additional, Oliva, Stefano, additional, Tarantini, Luigi, additional, Maurea, Nicola, additional, Rigacci, Luigi, additional, Petrolati, Sandro, additional, Casolo, Giancarlo, additional, and Bisceglia, Irma, additional

Published
2022
Full Text
View/download PDF

20. Pembrolizumab for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: Analysis of Prognostic Factors of Outcomes

Author

Tibaldi, Carmelo, primary, Mazzoni, Francesca, additional, Scotti, Vieri, additional, Vasile, Enrico, additional, Pozzessere, Daniele, additional, Stasi, Irene, additional, Camerini, Andrea, additional, Federici, Francesca, additional, Meoni, Giulia, additional, Caparello, Chiara, additional, Turrini, Marianna, additional, Rossi, Virginia, additional, Ciccone, Lucia Pia, additional, Pecora, Irene, additional, Fantechi, Beatrice, additional, Antonuzzo, Lorenzo, additional, Giannarelli, Diana, additional, and Baldini, Editta, additional

Published
2022
Full Text
View/download PDF

21. Case Series: Recovery of Chemotherapy-Related Acute Heart Failure by the Combined Use of Sacubitril Valsartan and Wearable Cardioverter Defibrillator: A Novel Winning Combination in Cardio-Oncology

Author

Canale, Maria Laura, primary, Coviello, Katia, additional, Solarino, Gianluca, additional, Del Meglio, Jacopo, additional, Simonetti, Federico, additional, Venturini, Elio, additional, Camerini, Andrea, additional, Maurea, Nicola, additional, Bisceglia, Irma, additional, Tessa, Carlo, additional, and Casolo, Giancarlo, additional

Published
2022
Full Text
View/download PDF

24. Italian Multicenter Phase III Randomized Study of Cisplatin–Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive Stage Small Cell Lung Cancer: Treatment Rationale and Protocol Design of the GOIRC-AIFA FARM6PMFJM Trial

Author

Tiseo, Marcello, Boni, Luca, Ambrosio, Francesca, Camerini, Andrea, Vitale, Maria Giuseppa, Baldini, Editta, Cinieri, Saverio, Zanelli, Francesca, Defraia, Efisio, Passalacqua, Rodolfo, Crino, Lucio, Dazzi, Claudio, Tibaldi, Carmelo, Turolla, Gianni M., DʼAlessandro, Vito, Zilembo, Nicoletta, Riccardi, Ferdinando, and Ardizzoni, Andrea

Published
2015
Full Text
View/download PDF

26. Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab

Author

Allegrini, Giacomo, Coltelli, Luigi, Orlandi, Paola, Fontana, Andrea, Camerini, Andrea, Ferro, Antonella, Cazzaniga, Marina, Casadei, Virginia, Lucchesi, Sara, Bona, Eleonora, Di Lieto, Marco, Pazzagli, Ilaria, Villa, Federica, Amoroso, Domenico, Scalese, Marco, Arrighi, Giada, Molinaro, Sabrina, Fioravanti, Anna, Finale, Chiara, Triolo, Renza, Di Desidero, Teresa, Donati, Sara, Marcucci, Lorenzo, Goletti, Orlando, Del Re, Marzia, Salvadori, Barbara, Ferrarini, Ilaria, Danesi, Romano, Falcone, Alfredo, and Bocci, Guido

Published
2014
Full Text
View/download PDF

27. Portrait of Italian Cardio-Oncology: Results of a Nationwide Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO) Survey

Author

Canale, Maria Laura, primary, Turazza, Fabio, additional, Lestuzzi, Chiara, additional, Parrini, Iris, additional, Camerini, Andrea, additional, Russo, Giulia, additional, Colivicchi, Furio, additional, Gabrielli, Domenico, additional, Gulizia, Michele Massimo, additional, Oliva, Stefano, additional, Tarantini, Luigi, additional, Maurea, Nicola, additional, Rigacci, Luigi, additional, Petrolati, Sandro, additional, Casolo, Giancarlo, additional, and Bisceglia, Irma, additional

Published
2021
Full Text
View/download PDF

28. INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIa-2)

Author

Bersanelli, Melissa, primary, Giannarelli, Diana, additional, De Giorgi, Ugo, additional, Pignata, Sandro, additional, Di Maio, Massimo, additional, Clemente, Alberto, additional, Verzoni, Elena, additional, Giusti, Raffaele, additional, Di Napoli, Marilena, additional, Aprile, Giuseppe, additional, Ermacora, Paola, additional, Catino, Annamaria, additional, Scotti, Vieri, additional, Mazzoni, Francesca, additional, Guglielmini, Pamela Francesca, additional, Veccia, Antonello, additional, Maruzzo, Marco, additional, Rossi, Ernesto, additional, Grossi, Francesco, additional, Casadei, Chiara, additional, Ficorella, Corrado, additional, Montesarchio, Vincenzo, additional, Verderame, Francesco, additional, Rizzo, Mimma, additional, Guaitoli, Giorgia, additional, Fratino, Lucia, additional, Accettura, Caterina, additional, Mencoboni, Manlio, additional, Zustovich, Fable, additional, Baldessari, Cinzia, additional, Cinieri, Saverio, additional, Camerini, Andrea, additional, Laera, Letizia, additional, Sorarù, Mariella, additional, Zucali, Paolo Andrea, additional, Guadalupi, Valentina, additional, Leonardi, Francesco, additional, Tiseo, Marcello, additional, Tognetto, Michele, additional, Di Costanzo, Francesco, additional, Pinto, Carmine, additional, Negrini, Giorgia, additional, Russo, Antonio, additional, Migliorino, Maria R, additional, Filetti, Marco, additional, and Buti, Sebastiano, additional

Published
2021
Full Text
View/download PDF

30. Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab

Author

Friedlaender, Alex, primary, Metro, Giulio, additional, Signorelli, Diego, additional, Gili, Alessio, additional, Economopoulou, Panagiota, additional, Roila, Fausto, additional, Banna, Giuseppe, additional, De Toma, Alessandro, additional, Camerini, Andrea, additional, Christopoulou, Athina, additional, Lo Russo, Giuseppe, additional, Banini, Marco, additional, Galetta, Domenico, additional, Jimenez, Beatriz, additional, Collazo-Lorduy, Ana, additional, Calles, Antonio, additional, Baxevanos, Panagiotis, additional, Linardou, Helena, additional, Kosmidis, Paris, additional, Mountzios, Giannis, additional, Garassino, Marina C., additional, and Addeo, Alfredo, additional

Published
2020
Full Text
View/download PDF

31. Poor performance status and front-line pembrolizumab in advanced non-small-cell lung cancer (NSCLC) patients with PD-L1>50%.

Author

Addeo, Alfredo, primary, Metro, Giulio, additional, Signorelli, Diego, additional, Economopoulou, Panagiota, additional, Roila, Fausto, additional, Banna, Giuseppe Luigi, additional, De Toma, Alessandro, additional, Camerini, Andrea, additional, Christopoulou, Athina, additional, Lo Russo, Giuseppe, additional, Galetta, Domenico, additional, Jimenez Munarriz, Beatriz, additional, Collazo, Ana, additional, Calles, Antonio, additional, Baxevanos, Panagiotis, additional, Linardou, Helena, additional, Kosmidis, Paris A., additional, Mountzios, Giannis Socrates, additional, Garassino, Marina Chiara, additional, and Friedlaender, Alex, additional

Published
2020
Full Text
View/download PDF

32. First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status

Author

Facchinetti, Francesco, primary, Mazzaschi, Giulia, additional, Barbieri, Fausto, additional, Passiglia, Francesco, additional, Mazzoni, Francesca, additional, Berardi, Rossana, additional, Proto, Claudia, additional, Cecere, Fabiana Letizia, additional, Pilotto, Sara, additional, Scotti, Vieri, additional, Rossi, Sabrina, additional, Del Conte, Alessandro, additional, Vita, Emanuele, additional, Bennati, Chiara, additional, Ardizzoni, Andrea, additional, Cerea, Giulio, additional, Migliorino, Maria Rita, additional, Sala, Elisa, additional, Camerini, Andrea, additional, Bearz, Alessandra, additional, De Carlo, Elisa, additional, Zanelli, Francesca, additional, Guaitoli, Giorgia, additional, Garassino, Marina Chiara, additional, Ciccone, Lucia Pia, additional, Sartori, Giulia, additional, Toschi, Luca, additional, Dall’Olio, Filippo Gustavo, additional, Landi, Lorenza, additional, Pizzutilo, Elio Gregory, additional, Bartoli, Gabriele, additional, Baldessari, Cinzia, additional, Novello, Silvia, additional, Bria, Emilio, additional, Cortinovis, Diego Luigi, additional, Rossi, Giulio, additional, Rossi, Antonio, additional, Banna, Giuseppe Luigi, additional, Camisa, Roberta, additional, Di Maio, Massimo, additional, and Tiseo, Marcello, additional

Published
2020
Full Text
View/download PDF

34. Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 ≥50% who progress on first-line immunotherapy: real-world data from a European cohort

Author

Metro, Giulio, primary, Addeo, Alfredo, additional, Signorelli, Diego, additional, Gili, Alessio, additional, Economopoulou, Panagiota, additional, Roila, Fausto, additional, Banna, Giuseppe, additional, Toma, Alessandro De, additional, Cobo, Juliana Rey, additional, Camerini, Andrea, additional, Christopoulou, Athina, additional, Russo, Giuseppe Lo, additional, Banini, Marco, additional, Galetta, Domenico, additional, Jimenez, Beatriz, additional, Collazo-Lorduy, Ana, additional, Calles, Antonio, additional, Baxevanos, Panagiotis, additional, Linardou, Helena, additional, Kosmidis, Paris, additional, Garassino, Marina C., additional, and Mountzios, Giannis, additional

Published
2019
Full Text
View/download PDF

38. Cardiovascular Risk Factors and Timing of Anthracyclines and Trastuzumab Cardiac Toxicity

Author

CANALE, MARIA LAURA, primary, CAMERINI, ANDREA, additional, HUQI, ALDA, additional, LILLI, ALESSIO, additional, BISCEGLIA, IRMA, additional, PARRINI, IRIS, additional, LESTUZZI, CHIARA, additional, DEL MEGLIO, JACOPO, additional, DONATI, SARA, additional, VENTURINI, ELIO, additional, SGAMBATO, ALESSANDRO, additional, TARANTINI, LUIGI, additional, AMOROSO, DOMENICO, additional, and CASOLO, GIANCARLO, additional

Published
2019
Full Text
View/download PDF

39. An individual patient-data meta-analysis of metronomic oral vinorelbine in metastatic non-small cell lung cancer

Author

Pujol, Jean-Louis, primary, Coffy, Amandine, additional, Camerini, Andrea, additional, Kotsakis, Athanasios, additional, Mencoboni, Manlio, additional, Gusella, Milena, additional, Pasini, Felice, additional, Pezzuto, Aldo, additional, Banna, Giuseppe Luigi, additional, Bilir, Cemil, additional, Samantas, Epaminontas, additional, Barlesi, Fabrice, additional, Roch, Benoît, additional, Guillou, Aude, additional, and Daurès, Jean-Pierre, additional

Published
2019
Full Text
View/download PDF

40. Syndrome of inappropriate anti-diuretic hormone secretion in cancer patients: results of the first multicenter Italian study

Author

Berardi, Rossana, primary, Mastroianni, Candida, additional, Lo Russo, Giuseppe, additional, Buosi, Roberta, additional, Santini, Daniele, additional, Montanino, Agnese, additional, Carnaghi, Carlo, additional, Tiseo, Marcello, additional, Chiari, Rita, additional, Camerini, Andrea, additional, Barni, Sandro, additional, De Marino, Valeria, additional, Ferrari, Daris, additional, Cristofano, Antonella, additional, Doni, Laura, additional, Freddari, Federica, additional, Fumagalli, Daniele, additional, Portalone, Luigi, additional, Sarmiento, Roberta, additional, Schinzari, Giovanni, additional, Sperandi, Francesca, additional, Tucci, Marcello, additional, Inno, Alessandro, additional, Ciuffreda, Libero, additional, Mariotti, Marita, additional, Mariani, Cinzia, additional, Caramanti, Miriam, additional, Torniai, Mariangela, additional, Gallucci, Rosaria, additional, Bennati, Chiara, additional, Bordi, Paola, additional, Buffoni, Lucio, additional, Galeassi, Achille, additional, Ghidini, Michele, additional, Grossi, Emidio, additional, Morabito, Alessandro, additional, Vincenzi, Bruno, additional, and Arvat, Emanuela, additional

Published
2019
Full Text
View/download PDF

41. Evaluation of HER2 and p53 expression in predicting response to docetaxel-based first-line chemotherapy in advanced breast cancer

Author

Martini Leonardo, De Luca Filomena, Valsuani Chiara, Tartarelli Gianna, Puccetti Cheti, Siclari Olimpia, Viacava Paolo, Donati Sara, Camerini Andrea, Cavazzana Andrea, and Amoroso Domenico

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background The human epidermal growth factor receptor 2 (HER2) and p53 pathways may be involved in chemotherapy sensitivity and/or resistance. We explore the value of HER2 and p53 status to foretell docetaxel sensitivity in advanced breast cancer. Methods HER2 and p53 expression was analysed in 36 (median age 55 yrs; range 37-87) metastatic breast cancer patients receiving docetaxel-based first-line chemotherapy. HER2 was determined by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), p53 was tested by IHC. We correlate the expression of study parameters with pathologic parameters, RECIST response and survival. The standard cut-off value of 2 was used to determine HER2 overexpression while p53 mean expression level was used to divide low/high expressors tumors. Results Median time to progression and overall survival were 9 (range 2 - 54) and 20 (range 3 - 101) months. Overall response rate was 41.6%. Nine cases showed HER2 overexpression. HER2 was more frequently overexpressed in less differentiated (p = 0.05) and higher stage (p = 0.003) disease. Mean FISH-HER2 values were significantly higher in responder than in non-responder pts (8.53 ± 10.21 vs 2.50 ± 4.12, p = 0.027). Moreover, HER2 overexpression correlates with treatment response at cross-tabulation analysis (p = 0.046). p53 expression was only associated with higher stage disease (p = 0.02) but lack of any significant association with HER status or docetaxel response. No significant relation with survival was observed for any parameter. Conclusion Our data seem to indicate that FISH-determined HER2 status but not p53 is associated with docetaxel sensitivity in metastatic breast cancer.

Published
2011
Full Text
View/download PDF

43. Prospective study on the role of cytidine deaminase activity in lung cancer patients treated with gemcitabine-platinum-based chemotherapy.

Author

Giovannetti, Elisa, primary, Tiseo, Marcello, additional, Honeywell, Richard J., additional, Boni, Luca, additional, Chartoire, Myriam, additional, Camerini, Andrea, additional, Mazzoni, Francesca, additional, Barbieri, Fausto, additional, Vittimberga, Isabella, additional, Peters, Godefridus J., additional, Rolfo, Christian Diego, additional, and Tibaldi, Carmelo, additional

Published
2018
Full Text
View/download PDF

45. Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: a multicenter retrospective analysis

Author

Santini, Daniele, primary, Ratta, Raffaele, additional, Pantano, Francesco, additional, De Lisi, Delia, additional, Maruzzo, Marco, additional, Galli, Luca, additional, Biasco, Elisa, additional, Farnesi, Azzurra, additional, Buti, Sebastiano, additional, Sternberg, Cora Nanette, additional, Cerbone, Linda, additional, Di Lorenzo, Giuseppe, additional, Spoto, Silvia, additional, Sterpi, Michelle, additional, De Giorgi, Ugo, additional, Berardi, Rossana, additional, Torniai, Mariangela, additional, Camerini, Andrea, additional, Massari, Francesco, additional, Procopio, Giuseppe, additional, and Tonini, Giuseppe, additional

Published
2017
Full Text
View/download PDF

46. Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial

Author

Tiseo, Marcello, primary, Boni, Luca, additional, Ambrosio, Francesca, additional, Camerini, Andrea, additional, Baldini, Editta, additional, Cinieri, Saverio, additional, Brighenti, Matteo, additional, Zanelli, Francesca, additional, Defraia, Efisio, additional, Chiari, Rita, additional, Dazzi, Claudio, additional, Tibaldi, Carmelo, additional, Turolla, Gianni Michele, additional, D’Alessandro, Vito, additional, Zilembo, Nicoletta, additional, Trolese, Anna Rita, additional, Grossi, Francesco, additional, Riccardi, Ferdinando, additional, and Ardizzoni, Andrea, additional

Published
2017
Full Text
View/download PDF

49. Cytidine deaminase enzymatic activity is a prognostic biomarker in gemcitabine/platinum-treated advanced non-small-cell lung cancer: a prospective validation study.

Author

Tibaldi, Carmelo, Camerini, Andrea, Tiseo, Marcello, Mazzoni, Francesca, Barbieri, Fausto, Vittimberga, Isabella, Brighenti, Matteo, Boni, Luca, Baldini, Editta, Gilli, Annalisa, Honeywell, Richard, Chartoire, Myriam, Peters, Godefridus J., Giovannetti, Elisa, on behalf of The Italian Oncological Group of Clinical Research (GOIRC), and Italian Oncological Group of Clinical Research (GOIRC)

Abstract

Background: Cytidine deaminase (CDA) plays a crucial role in the degradation of gemcitabine. In our previous retrospective study, CDA enzymatic activity was the strongest prognostic biomarker of the activity and efficacy of platinum/gemcitabine combinations. The aim of this prospective study was to validate the prognostic role of CDA activity in the first-line treatment of advanced non-small-cell lung cancer.Methods: A total of 124 untreated patients received standard doses of platinum/gemcitabine. CDA activity was baseline measured in plasma samples by spectrophotometric assay.Results: Using the median CDA level as cut-off, in the patients with high versus low CDA activity the response rate was 25.0% (95% CI, 14.7-37.8) and 54.1% (95% CI, 40.8-66.9), P = 0.0013; the 6-month progression rate was 34.5% (95% CI, 22.6-46.6) and 54.1% (95% CI, 40.9-65.6), HR = 2.01 (95% CI, 1.32-3.06), P < 0.001; the 1-year survival rate was 23.3% (95% CI, 13.6-34.6) and 57.3% (95% CI, 43.9-68.6), HR = 2.20 (95% CI, 1.46-3.34), P = 0.0002, respectively. CDA activity resulted to be an independent prognostic factor for progression and survival at multivariate analysis.Conclusions: This study validated prospectively the prognostic role of the CDA activity and should prompt larger and adequately designed randomised prospective studies to establish the predictive impact of this test in improving the outcome of selected patients. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results